Detalhe da pesquisa
1.
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
Nat Immunol
; 22(6): 769-780, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34017122
2.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
3.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
4.
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol
; 199(3): 355-365, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111391
5.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
6.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325490
7.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
8.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087126
9.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
10.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
11.
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Br J Haematol
; 194(1): 83-91, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33942292
12.
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
Eur J Haematol
; 107(4): 428-435, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137077
13.
Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study.
Haematologica
; 108(2): 621-626, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263839
14.
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Br J Haematol
; 179(3): 430-438, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28832957
15.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet
; 387(10020): 770-8, 2016 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26673811
16.
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.
Haematologica
; 107(7): 1726-1730, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295081
17.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Haematologica
; 102(10): 1796-1805, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751558
18.
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Brain Behav Immun
; 66: 156-164, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28676350
19.
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
Haematologica
; 106(8): 2257-2260, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657786
20.
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.
Br J Clin Pharmacol
; 80(4): 687-97, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25847183